227 related articles for article (PubMed ID: 11468419)
1. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
2. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
3. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
4. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
Sankatsing SU; Cornelissen M; Kloosterboer N; Crommentuyn KM; Bosch TM; Mul FP; Jurriaans S; Huitema AD; Beijnen JH; Lange JM; Prins JM; Schuitemaker H
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):19-27. PubMed ID: 17263628
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
Lucia MB; Rutella S; Leone G; Larocca LM; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):369-78. PubMed ID: 12138343
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.
Sánchez Mdel C; López P; Vélez R; Yamamura Y
Ethn Dis; 2008; 18(2 Suppl 2):S2-60-4. PubMed ID: 18646322
[TBL] [Abstract][Full Text] [Related]
10. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
13. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.
Chandler B; Almond L; Ford J; Owen A; Hoggard P; Khoo S; Back D
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):551-6. PubMed ID: 12902797
[TBL] [Abstract][Full Text] [Related]
14. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Phenix BN; Angel JB; Mandy F; Kravcik S; Parato K; Chambers KA; Gallicano K; Hawley-Foss N; Cassol S; Cameron DW; Badley AD
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):559-67. PubMed ID: 10777146
[TBL] [Abstract][Full Text] [Related]
15. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
Zha W; Wang G; Xu W; Liu X; Wang Y; Zha BS; Shi J; Zhao Q; Gerk PM; Studer E; Hylemon PB; Pandak WM; Zhou H
PLoS One; 2013; 8(1):e54349. PubMed ID: 23372711
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection.
Donnenberg VS; Burckart GJ; Zeevi A; Griffith BP; Iacono A; McCurry KR; Wilson JW; Donnenberg AD
Transplantation; 2004 Jun; 77(11):1699-706. PubMed ID: 15201669
[TBL] [Abstract][Full Text] [Related]
20. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
